Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer.
Chemoradiation therapy (CRT)
metastases
non-small cell lung cancer (NSCLC)
specific growth rate (SGR)
tumor volume
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
entrez:
26
4
2019
pubmed:
26
4
2019
medline:
26
4
2019
Statut:
ppublish
Résumé
Locally advanced non-small cell lung cancer (NSCLC) may exhibit significant tumor growth before the initiation of definitive chemoradiation therapy (CRT). We thus investigated the prognostic value of pretreatment tumor growth rate as measured by specific growth rate (SGR). We conducted a retrospective review of 42 patients with locally advanced NSCLC treated with definitive concurrent CRT. For each patient, we contoured the primary gross tumor volume (GTV) on the pretreatment diagnostic chest computed tomography (CT) scan and the radiation therapy (RT) planning CT scan. We then calculated SGR based on the primary GTV from each scan and the time interval between scans. We used log-rank tests and univariate Cox regression models to quantify differences in progression-free survival (PFS), overall survival (OS) and recurrence based on SGR. We divided patients into two groups for analysis: those with an SGR greater than or equal to the upper tercile value of 0.94%/day (high SGR) and those with SGR less than 0.94%/day (low SGR). Patients with high SGRs versus low SGRs experienced inferior PFS (median, 5.6 Pretreatment SGR was associated with inferior PFS and distant control among patients with locally advanced NSCLC treated with concurrent CRT. Further studies in larger populations may aid in elucidating optimal SGR cut-off points for risk stratification.
Sections du résumé
BACKGROUND
BACKGROUND
Locally advanced non-small cell lung cancer (NSCLC) may exhibit significant tumor growth before the initiation of definitive chemoradiation therapy (CRT). We thus investigated the prognostic value of pretreatment tumor growth rate as measured by specific growth rate (SGR).
METHODS
METHODS
We conducted a retrospective review of 42 patients with locally advanced NSCLC treated with definitive concurrent CRT. For each patient, we contoured the primary gross tumor volume (GTV) on the pretreatment diagnostic chest computed tomography (CT) scan and the radiation therapy (RT) planning CT scan. We then calculated SGR based on the primary GTV from each scan and the time interval between scans. We used log-rank tests and univariate Cox regression models to quantify differences in progression-free survival (PFS), overall survival (OS) and recurrence based on SGR.
RESULTS
RESULTS
We divided patients into two groups for analysis: those with an SGR greater than or equal to the upper tercile value of 0.94%/day (high SGR) and those with SGR less than 0.94%/day (low SGR). Patients with high SGRs versus low SGRs experienced inferior PFS (median, 5.6
CONCLUSIONS
CONCLUSIONS
Pretreatment SGR was associated with inferior PFS and distant control among patients with locally advanced NSCLC treated with concurrent CRT. Further studies in larger populations may aid in elucidating optimal SGR cut-off points for risk stratification.
Identifiants
pubmed: 31019945
doi: 10.21037/atm.2019.02.14
pii: atm-07-05-95
pmc: PMC6462644
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95Déclaration de conflit d'intérêts
Conflicts of Interest: Dr. Jabbour has received research funding from Merck and Nestle. Dr. Malhotra is on the advisory board of Astra-Zeneca and Pfizer and has received research funding from Oncoceutics. The other authors have no conflicts of interest to declare.
Références
Chest. 2003 Feb;123(2):463-7
pubmed: 12576367
Cancer Res. 2007 Apr 15;67(8):3970-5
pubmed: 17440113
Acta Oncol. 2009;48(4):591-7
pubmed: 19330565
Radiother Oncol. 2010 Jan;94(1):1-11
pubmed: 20074823
Cancer. 2010 Nov 1;116(21):5030-7
pubmed: 20623786
J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60
pubmed: 21903745
Clin Lung Cancer. 2014 Jan;15(1):79-85
pubmed: 24238934
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):532-8
pubmed: 24929163
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):627-33
pubmed: 26068495
Transl Lung Cancer Res. 2017 Apr;6(2):113-118
pubmed: 28529894
J Thorac Oncol. 2017 Dec;12(12):1779-1787
pubmed: 28843360
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Cancer. 1994 Oct 15;74(8):2239-44
pubmed: 7922975
Jpn J Clin Oncol. 1994 Aug;24(4):199-204
pubmed: 8072198